Alcohol-Associated Liver Disease Flashcards
In patients w/ chronic hepatitis C virus infection, we recommend avoiding consumptions of alcohol.
strong, high evidence
In patients w/ chronic hepatitis B virus infection, we recommend avoiding consumption of alcohol.
strong, low evidence
In adults being screened for alcohol use, we recommend the use of brief screening tools, such as the Alcohol Use Disorders Identification Test-Consumption tool.
strong, high evidence
In patient w/ compensated ALD, we recommend use of baclofen as an option for treatment of AUD.
strong, moderate evidence
In patient w/ compensated ALD, we suggest use of acamprosate or naltrexone as an option for treatment of AUD.
conditional, very low evidence
In patients w/ compensated ALD, we suggest use of gabapentin or topiramate as an option for treatment of AUD.
conditional, very low evidence
We suggest against the use of disulfiram in the treatment of aUD along any spectrum of ALD. Disulfiram should not be used in the treatment of AUD along any spectrum of ALD.
conditional, very low evidence
In patients w/ ALD and severe alcohol withdrawal syndrome, we recommend cautious use of benzodiazepines as treatment of choice, and careful monitoring given their potential to precipitate or exacerbate hepatic encephalopathy.
strong, moderate evidence
In hospitalized patients w/ severe AH, we recommend against universal administration of prophylactic antibiotics.
strong, moderate evidence
In patient w/ severe AH (MELD > 20), we recommend treatment w/ corticosteroid therapy.
strong, moderate evidence
We recommend against the use of pentoxifylline for individuals w/ severe AH.
strong, moderate evidence
The are insufficient data to determine the role of granulocyte colony stimulating factor and microbiome-based therapies in the treatment of severe AH.
conditional, moderate evidence
We recommend use of intravenous N-acetyl cysteine as an adjuvant to corticosteroids in patients w/ severe AH.
strong, moderate evidence
